EGFR and non-small cell lung carcinoma: A phase II trial by Roselle and colleagues was the first to demonstrate the efficacy of this combination in the EGFR-mutant subgroup, and several other randomized controlled trials (RCTs) have shown the prolongation of PFS and objective response rate (ORR) in advanced NSCLC with erlotinib plus bevacizumab [12].